BiotechTube

Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Sedation in Non-intubated Diagnostic and Therapeutic Procedures

Conditions

Sedation in Non-intubated Diagnostic and Therapeutic Procedures

Trial Timeline

Jan 1, 2024 → Mar 1, 2024

NCT ID
NCT06216444

About Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection

Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection is a approved stage product being developed by Jiangsu Hengrui Medicine for Sedation in Non-intubated Diagnostic and Therapeutic Procedures. The current trial status is unknown. This product is registered under clinical trial identifier NCT06216444. Target conditions include Sedation in Non-intubated Diagnostic and Therapeutic Procedures.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06216444ApprovedUNKNOWN

Competing Products

20 competing products in Sedation in Non-intubated Diagnostic and Therapeutic Procedures

See all competitors
ProductCompanyStageHype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3
77
Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
85
fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
85
AQUAVAN® (fospropofol disodium) InjectionEisaiPhase 2/3
65
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
52
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
77
Remimazolam TosilateJiangsu Hengrui MedicineApproved
85
Remimazolam TosilateJiangsu Hengrui MedicinePhase 1/2
41
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
23
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
77
Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3
77
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
77
SHR0302 Base Gel + SHR0302 Base Gel PlaceboJiangsu Hengrui MedicinePhase 1
33
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
23
Remimazolam Tosilate for injection + Propofol InjectionJiangsu Hengrui MedicinePhase 2/3
65
Dexmedetomidine hydrochloride nasal spray + Dexmedetomidine hydrochloride nasal spray blank preparation.Jiangsu Hengrui MedicinePhase 1
33
Intranasal Dexmedetomidine + Intravenous Dexmedetomidine + Intranasal Placebo + Intravenous PlaceboJiangsu Hengrui MedicinePhase 1
33
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 2
52
dexmedetomidine nasal spray + dexmedetomidine hydrochloride nasal spray blank preparationJiangsu Hengrui MedicinePhase 2/3
65
Remimazolam Tosilate + Propofol Injection.Jiangsu Hengrui MedicinePhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85